HIGH-RISK LARGE B-CELL LYMPHOMA (LBCL)

Clinical trials for HIGH-RISK LARGE B-CELL LYMPHOMA (LBCL) explained in plain language.

Never miss a new study

Get alerted when new HIGH-RISK LARGE B-CELL LYMPHOMA (LBCL) trials appear

Sign up with your email to follow new studies for HIGH-RISK LARGE B-CELL LYMPHOMA (LBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Revolutionary immune cell therapy battles aggressive blood cancer Head-On

Disease control Recruiting now

This study compares a personalized immune cell therapy (CAR-T) against standard chemotherapy as the first treatment for people with high-risk, aggressive lymphoma. The trial will enroll 300 participants who have just started treatment to see if CAR-T therapy can better control th…

Matched conditions: HIGH-RISK LARGE B-CELL LYMPHOMA (LBCL)

Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control

Last updated Mar 12, 2026 13:50 UTC

HIGH-RISK LARGE B-CELL LYMPHOMA (LBCL)

Get alerted when new HIGH-RISK LARGE B-CELL LYMPHOMA (LBCL) trials appear

Revolutionary immune cell therapy battles aggressive blood cancer Head-On